Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy

Richard Hughes, F. MedSci, Siân Bensa, Hugh Willison, Peter Den Van Bergh, Giancarlo Comi, Isabel Illa, Eduardo Nobile-Orazio, Pieter Van Doorn, Marinos Dalakas, Martin Bojar, Anthony Swan

Research output: Contribution to journalArticlepeer-review

Abstract

This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 mg daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Twenty-four of the thirty-two randomized patients completed both treatment periods. Both treatments produced significant improvements in the primary outcome measure, change in an ll-point disability scale two weeks after randomization. There was slightly, but not significantly, more improvement after Mg than with prednisolone, the mean difference between the groups in change in disability grade being 0.16 (95% CI = -0.35 to 0.66). There were also slightly, but not significantly, greater improvements favoring IVIg in the secondary outcome measures: time to walk 10 meters after two weeks and improvement in disability grade after six weeks. Results may have been biased against IVIg by the eight patients who did not complete the second arm of the trial. A serious adverse event (psychosis) attributable to treatment occurred in one patient while on prednisolone and in none with IVIg.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalAnnals of Neurology
Volume50
Issue number2
DOIs
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy'. Together they form a unique fingerprint.

Cite this